On December 13, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the fourth quarter and full fiscal year 2024 that ended September 30, 2024 and provided a business update. The company is continuing to advance its pipeline, which includes EB06, and anti-CXCL10 monoclonal antibody for the treatment of vitiligo, EB05 for the treatment of acute respiratory distress syndrome (ARDS) and pulmonary fibrosis, and EB01 for the treatment of allergic contact dermatitis (ACD). We anticipate an IND being filed before the end of 2025 for EB06 such that a Phase 2 clinical trial can initiate in 2026. EB05 is currently being tested in a Phase 2, government-sponsored trial with results expected by the end of 2026. Following a successful P2b trial for EB01 in ACD, the company is in active partnering discussions to advance that program into late stage trials.
